Biologics and Advanced Therapies Contract Manufacturing: Public Market Update

About the Report

The public biologics and advanced therapeutics (ATs) contract development and manufacturing organization (CDMO) market is experiencing dynamic growth, fueled by advancements in biomanufacturing and gene editing, increased investments in global manufacturing capacity, and strategic partnerships. While 2023 proved to be a challenging year, in 2024, biologics and ATs manufacturers steadily recovered in public markets. This trend is expected to continue, supported by improving capital market conditions and a heightened regulatory focus on insourcing and near-sourcing.

Looking ahead, projections for 2025 indicate renewed momentum in both public and private investments, signaling the evolution of a more mature market increasingly centered on scalable and efficient manufacturing solutions.

This report offers a comprehensive analysis of publicly traded companies in the sector. It examines the performance and strategies of global leaders, regional specialists, and niche innovators, providing detailed insights into pipelines, financial trends, and the impact of technological advancements.